menu
    • menu

    Company profile for Oligomerix

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Oligomerix is an early-stage biotech company founded in November 2006 with the primary goal of developing a proprietary platform technology for drug discovery and biomarker development for central nervous system (CNS) disorders focused on AD, and to use that platform to discover unique, drug-like small molecules that inhibit tau self-association into toxic oligomers. The Company has advanced its technologies using its equity i...
    Oligomerix is an early-stage biotech company founded in November 2006 with the primary goal of developing a proprietary platform technology for drug discovery and biomarker development for central nervous system (CNS) disorders focused on AD, and to use that platform to discover unique, drug-like small molecules that inhibit tau self-association into toxic oligomers. The Company has advanced its technologies using its equity investment, NIH grant awards, and the Alzheimer’s Drug Discovery Foundation (ADDF). The Company has built a sound business model around its core technologies, a strong intellectual property (IP) position.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    OligomerixUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2 Westchester Park Drive, Suite 208 White Plains, NY 10604
    Telephone
    Telephone
    917-912-4088
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://oligomerix.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/oligomerix-inc/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/Oligomerix?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Oligomerix Secures $0.5M NIH Grant For OLX-07010 Safety Studies
    Oligomerix Secures $0.5M NIH Grant For OLX-07010 Safety Studies

    18 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251118029300/en/Oligomerix-Awarded-%240.5-M-phase-I-NIH-SBIR-Fast-Track-Grant-to-Conduct-Safety-Studies-that-will-Support-Clinical-Studies-of-OLX-07010-for-Alzheimers-Patients

    BUSINESSWIRE
    18 Nov 2025
    Share Share
    Oligomerix Elects New Chairman William Caple to Board
    Oligomerix Elects New Chairman William Caple to Board

    03 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-03/oligomerix-elects-new-chairman-william-caple-to-board-of-directors

    PHARMAWEB
    03 Sep 2025
    Share Share
    Oligomerix Publishes Results on Preclinical Study for Alzheimer's
    Oligomerix Publishes Results on Preclinical Study for Alzheimer's

    12 Mar 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250312573127/en

    BUSINESSWIRE
    12 Mar 2025
    Share Share
    Oligomerix Publishes Data on Novel Small Molecule Therapeutic in Development for Alzheimer’s Disease
    Oligomerix Publishes Data on Novel Small Molecule Therapeutic in Development for Alzheimer’s Disease

    09 Aug 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230809142059/en

    BUSINESSWIRE
    09 Aug 2023
    Share Share
    Oligomerix Announces Dosing of Tau Self-Association Inhibitor OLX-07010
    Oligomerix Announces Dosing of Tau Self-Association Inhibitor OLX-07010

    02 Feb 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230202005336/en

    BUSINESSWIRE
    02 Feb 2023
    Share Share
    Oligomerix Presents Data from IND-Enabling Studies on Clinical (CTAD)
    Oligomerix Presents Data from IND-Enabling Studies on Clinical (CTAD)

    30 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221130005318/en

    BUSINESSWIRE
    30 Nov 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search